Evolution Summit 2020
02 March 2019 - 04 March 2019
The 21st Evolution Summit is an invitation-only, premium Summit bringing leading clinical trial executives and innovative suppliers and solution providers together. The Summit’s content is aligned with key clinical trial challenges and interests, relevant market developments, and practical and progressive ideas and strategies adopted by successful pioneers.
The Meritage Resort & Spa, Napa Valley, CA, USA
https://events.marcusevans-events.com/evo2020/
Venture Summit / West
06 March 2019 - 07 March 2019
Meet, interact and network with more than 1,000 VCs, Corporate VCs, angel investors, investment bankers and founders of venture backed, emerging and early stage companies on the dedicated Lifesciences/Healthcare Track at the prestigious Venture Summit | West being held on March 6th – 7th 2019 at the Hyatt Regency, San Francisco, CA.
A highly productive venture conference, Venture Summit | West is dedicated to showcasing VCs, Corporate VCs and angel investors committed to funding venture backed, emerging and early stage companies.
Special Offer:
Drug Discovery Today has made special arrangements for our network to receive a special discount of 10% off the existing “early bird" rates.
This conference will be attended by the best people in the industry. Please register early to avoid disappointment.
Register Today & Save (Use promo code "DDTVIP”)
In addition to providing access to leading Investors, the conference will feature more than 50 pre-screened venture backed, emerging and early stage companies seeking capital, and hardcore networking.
Hyatt Regency, San Francisco, CA, USA
https://www.youngstartup.com/west2019/?utm_source=IPs&utm_campaign=Drug%20Discovery%20Today
Pharmacogenetics and Stratified Medicine Network
06 March 2019
This year we are proud to welcome eminent speakers Professors Dan Roden, Mary Relling and Kathy Giacomini from the USA and UK Professors Chas Bountra, Chris Holmes, Phil Beales, Phil Quirke and Dr Nicola Strickland to present at our 6th Annual Open Meeting.
There will be presentations on implementing pharmacogenomics in paediatrics / rare disease and in the role of membrane transporters in regulating drug disposition & distribution. Value of biobanks and electronic health records to precision medicine; and how partnerships with pharmaceutical companies are accelerating pioneer treatments.
Early career speakers will highlight the role of epigenomics in precision medicine, the importance of rare variants in pharmacogenomics and introduce the recently launched NHS Genomic Medicine Service.
A patient will give an account of their experience of personalised medicine.
Experts in AI will show how the advances in health informatics are offering personalised medicine treatment, and how AI in radiology / pathology is improving the diagnosis of disease.
The meeting attracts experts from across all sectors so provides excellent networking opportunities to meet colleagues from different backgrounds.
Opportunities to exhibit the expertise of your organisation are available please contact Christine cjmcn@liv.ac.uk for more details
Royal College of Physicians, London, UK
http://www.uk-pgx-stratmed.co.uk/index.php/component/jevents/eventdetail/426/12%7C22/6th-annual-open-meeting-ukpgx2019.html
SMi’s 3rd Annual Drug Discovery Chemistry
18 March 2019 - 19 March 2019
CHAIRED BY: Roderick Hubbard, Senior Fellow, Vernalis Research Ltd and Darren Green, Director of Molecular Design, GSK
SMi is proud to present its 3rd Annual Drug Discovery Chemistry event, taking place on the 18th-19th March 2019. The fight to optimise the drug discovery process is on as there is currently a reduced output of new medicines within the market, however, demand for novel drugs is still steadily increasing.
This year’s event will specifically focus on innovations within the field that has the potential to drive the pharmaceutical industry into a new era of medicines, with optimization of the R&D process to become cheaper, faster and increasing the likelihood of drug efficacy and success. These are some of the major obstacles within drug discovery at present, as the process is overall long, expensive and often potential drugs will fail late in clinical trials, wasting resources and time.
The event will also focus on novel techniques that can be implemented within the field today that can identify new druggable targets and possibly open new therapeutic areas within the clinic. This could offer opportunities for pharmaceutical companies to produce medicines for diseases and ailments that have previously not been targeted, and likewise, offer new drug targets for existing diseases that could potentially offer better clinical outcomes, such as within the development of cancer drugs.
Drug Discovery Chemistry 2019 will look at various developments within the field, guiding companies on how they can best utilize the newest technologies and drug discovery modalities to develop new medicines, reduce their R&D cost and timelines, and ultimately, increase their medicine output for commercial success.
Event Hashtag: #SMiDrugDisChem
Copthorne Tara Hotel, London, UK
https://www.smi-online.co.uk/pharmaceuticals/uk/Drug-Discovery-UK?utm_medium=www.drug-discovery.co.uk&utm_source=P-279&utm_campaign=drugdistoday
Superbugs and Superdrugs 2019
18 March 2019 - 19 March 2019
Inspiring the global commitment required to tackle multidrug-resistance among bacteria populations, as the global threat of antimicrobial resistance continues to grow.
This year’s event will gather leaders from pharmaceutical companies, academia and the wider scientific community together with regulatory agencies and public-private partnerships, to discuss the growing threat of antibiotic resistance.
Join us to learn about various strategies in place to support antimicrobial resistance research & development, evaluate the latest scientific advancements for tackling antimicrobial resistance and consider potential novel candidates and alternatives to anti-microbials.
The event will also focus on the strategies pharmaceutical companies use to assist the development of new therapeutics & drugs, how to obtain funding for new projects and address why there is a current lack of incentives for researchers working in antimicrobial resistance research and development.
London, UK
http://www.superbugssuperdrugs.com/ddtwb
Innate Killer Summit 2019
19 March 2019 - 21 March 2019
The 4th Innate Killer Summit is an annual industry meeting providing a platform for leaders in the NK field to network, interact and learn at the only end-to-end meeting that fosters the transformation of leading science to commercial therapies.
As the understanding of NK cells improves year on year, the challenges of producing effective NK cell therapies are top priorities to overcome. Manufacturing processes need to be streamlined and regulatory landscapes better understood. It is imperative that we can come together to exchange ideas to overcome the hurdles of getting the best immunotherapies to patients in need.
In addition to accessing cutting-edge novel innovations and the latest clinical data, leave the Innate Killer Summit fully equipped to progress your NK cell therapy pipeline with a forward-looking plan for global manufacturing.
Join the leading scientific and business experts from all the key stakeholders to identify future approaches to deliver commercially viable off-the-shelf therapies.
Hilton San Diego Gaslamp Quarter, San Diego, CA, USA
https://innate-killer.com/
13th Göttingen Meeting of the German Neuroscience Society
20 March 2019 - 23 March 2019
The Göttingen Meeting of the German Neuroscience Societies is one of the largest multi-disciplinary neuroscience meetings in Europe with around 1.700 participants. It covers a wide range of research fields in the neurosciences including vertebrate and invertebrate systems, molecular, cellular and systemic neurobiology, neuropharmacology, developmental, computational, behavioral, cognitive and clinical neuroscience.
Geisteswissenschaftliches Zentrum, Georg-August-Universität in Göttingen
https://www.nwg-goettingen.de/
Royal Society of Medicine - Spotlight on Whistleblowing
26 March 2019
This meeting will bring together policy-makers, researchers, clinicians and other healthcare professionals to understand the climate for whistleblowers within the NHS. Themes will include the impact on patient safety of dysfunctional teams. There will be personal viewpoints from patient and doctor, and the keynote speaker will be Caroline Dinenage, Minister of State for Care. The panel of speakers will include Mr Justice O’Hara, who led the inquiry into the deaths from hyponatraemia of five children in Northern Ireland; Professor Mike Bewick, Deputy Medical Director, NHS England; and Dame Clare Marx, Chair, General Medical Council.
Royal Society of Medicine, 1 Wimpole Street, London, W1G 0AE
https://www.rsm.ac.uk/
Occupational health in the performing arts: The original gig economy
27 March 2019
The performing and visual arts sector contributes more than £5.4 billion a year to the UK economy. The most recent statistics show that this industry accounts for around 5.6% of total UK jobs. This meeting will explore how the health of performers, and the self-employed more broadly in the context of the gig economy, can be better supported. The keynote speaker will be Professor Aaron Williamon, Professor of Performance Science, Royal College of Music and Imperial College London. BBC Radio 4 newsreader Mr Zeb Soanes will give a performer’s perspective and Mr Colin Thomas, Chief Medical Officer at the BBC will discuss emerging occupational health issues in broadcasting, including meeting the health and work needs of freelance workers. Dr Rob Hampton, Public Health England Medical Champion for Work, will offer thoughts on the self-employed and the gig economy from a public health, occupational health and GP perspective.
Royal Society of Medicine, 1 Wimpole Street, London, W1G 0AE
https://www.rsm.ac.uk/events/occupational-medicine/2018-19/omm02/
Psychiatry in dialogue with society – distinguished lecture
28 March 2019
During this lecture Sir Michael Rutter, Professor of Developmental Psychopathology at the Institute of Psychiatry, Psychology and Neuroscience, King’s College London, will present the concepts and findings on nature-nurture interplay as they apply to mental disorders. There cannot be any meaningful subdivision into ‘good’ genes and ‘bad’ genes. The idea that the level of heritability sets limits on what can be modified is misleading, as is the partially wrong claim that the genetic findings on traits in the general population are the same as those applying to clinically defined extreme groups.
Royal Society of Medicine, 1 Wimpole Street, London, W1G 0AE
https://www.rsm.ac.uk/events/psychiatry/2018-19/pym03/